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Improving access to essential medicines through 
PUBLIC-PRIVATE PartnershipS IN EAST AFRICA
INTRODUCTION 
Pharmaceutical production is unevenly dispersed globally, with majority of the manufacturing work concentrated in 
a few sites, mostly in developed countries. 
According to the World Health Organisation 
(WHO) World Medicines Situation Report, 
two-thirds of the value of medicines 
produced globally is accounted for by 
firms with headquarters located in just five 
countries - the USA, Japan, Germany, France 
and the UK. 
The research-based multinational pharma 
companies from these countries have 
continued to spend, on average, ~17% of 
their revenues for research and development 
(R&D) work to develop new medicines to 
save human lives. From such investments, 
tremendous reports on new formulations 
to address several ailments have been 
highlighted. 
The US Food and Drug Authority (US-FDA), 
through their Center for Drug Evaluation 
and Research (CDER), revealed that about 
28 novel drugs were approved in the period 
2005 – 2015, giving hope for hard-to-treat 
diseases1. Additionally, the International 
Federation of Pharmaceutical Manufacturers 
& Associations (IFPMA) showed that there 
were 2.5 million AIDS-related deaths in 2005 
compared to 1.1 million in 20152. 
This was attributed to the introduction of 
ARVs, which were new at the time. Due to 
increase in the burden of non-communicable 
diseases (NCD), research-based pharma 
industry has also recognised this challenge 
and is committed to carry out research in 
this area. 
WHO has also identified 17 neglected 
tropical diseases (NTDs) that affect 
many people, predominantly from the 
poor setting, and have rallied all players, 
including pharma to develop products 
to address the scourge. Considering that 
development of pharmaceuticals and 
new therapies is costly, there is need to 
leverage on partnerships.
This will allow for concerted effort to 
ensure end-products are affordable. 
In this case, the support and funding 
for R&D for NTDs is mainly through 
collaborations and partnerships 
that bring together expertise from 
academia, industry, private foundations 
and governments, and funded by 
philanthropic organisations in the 
research-based industry. 
In 2014, the research-based industry 
invested over US$ 543 million for NTDs 
research work. This demonstrates 
that industry-academia synergistic 
partnerships, enabled by sound policies 
and regulatory systems are fundamental 
for development and funding of robust 
health systems3. This in turn creates a 
Research and Development (R&D) 
is a critical aspect of innovation 
that is necessary for economic 
development and prosperity. 
Product development process is 
lengthy and costly, and adherence 
to strict regulatory requirements is 
mandatory. 
Public-Private Partnerships (PPPs) 
have been identified as one of the 
solutions for addressing challenges 
in pharmaceutical innovation 
where capacity in research by 
the private sector is deemed 
insufficient. Industry-research 
institution partnerships should be 
established in the EAC region.
EAC partner states should 
stimulate PPPs by directing 
the R&D agenda, funding 
pharmaceutical research 
and formulating policies that 
encourage product development.
1CDER January 2016 summary report
2The Pharmaceutical Industry and Global Health, Facts & 
Figures 2017
3Local production of pharmaceuticals and health system 
strengthening in Africa; An Evidence Brief; A publication in the 
German Health Practice Collection.
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creams and ointments for various 
therapeutic uses. More supportive 
policies and local partnerships can 
help bolster the small gains achieved 
so far.
The Government of Ethiopia is leading 
the way in demonstrating this through 
their industrial policy and health 
policy attributes that have accelerated 
growth of local pharmaceutical 
producers (LPP)6. Learning from 
previous policy lapses, the current 
policy under implementation is more 
progressive with positive successes 
in industrial development, including 
improved quality infrastructure and 
availability of quality medicines.
Similar efforts have been seen 
in Uganda, Tanzania and Kenya 
even though proactive research 
partnerships remain low. Furthermore, 
EAC governments have not been able 
to create a framework within which 
government priority needs are linked 
to industry/research/academia groups. 
This has been attributed to a weak 
policy advocacy environment - both in 
the public and private sector.
 
In view of the above, this ACTs project 
was conceptualised to establish 
the innovation capacity of the East 
Africa pharmaceutical manufacturing 
industry, to identify the barriers 
to public/-private partnerships 
and establish a framework for an 
impactful pharmaceutical cross-sector 
partnership system for improved 
access in essential medicines. 
The main objectives of the study were;
1. To determine the level of 
production competence of 
the pharmaceutical industry 
in East Africa region regarding 
manufacture of national essential 
medicines. 
2. To identify factors that contribute 
to the product gap between the 
national essential medicines 
lists and medicines that are 
manufactured in the region. 
3. To establish mitigation strategies 
to reduce the product gap 
between the national essential 
conducive climate for investment in 
the pharmaceutical sector. As such, 
forming strategic partnerships with 
different organisations is a crucial part 
of our research and development 
process.
For instance, GlaxoSmithKline (GSK) 
has over 500 research partnerships 
with universities and academic 
institutions globally, and provides 
support for science students through 
fellowships to advance scientific 
understanding and research capacity. 
GSK’s approach is drawn from 
historical happenings of the 1940s 
when the transformation of the US 
pharmaceutical industry took place, 
because the government partnered 
with 17 manufacturers to produce 
penicillin, which was urgently needed4. 
Just like in the US, India’s 
pharmaceutical industry experienced 
meteoric growth when the 
government proactively crafted policy 
interventions like tax, partnerships, 
technology, and legal provisions for 
the manufacturing sector5, which 
has made their pharma industry 
the largest provider of generic 
medicines globally. In India, R&D is 
realised through partnerships and 
joint ventures (JVs). This has led to 
growth of the domestic market that 
is projected to increase from an 
estimated US$11 billion in March 2009 
to approximately US$30 billion by 
2020. 
On the other hand, African countries 
produce approximately 30% of the 
national’s medicines requirement; yet 
of the more than two billion people 
worldwide that have sub-optimal 
access to the medicines they need, 
majority reside in Africa. The low 
investment of manufacturing in Africa 
is a function of many aspects that 
include technical capacity, human 
resource, financing and conducive 
policy environments for pharma 
manufacturing. Nonetheless, Africa 
pharma have demonstrated some 
level of expertise and currently 
produce various products, i.e. finished 
products such as tablets, capsules, 
3Local production of pharmaceuticals and health system 
strengthening in Africa; An Evidence Brief; A publication in 
the German Health Practice Collection.
4Younkin, P. (2008). Making the Market: How the 
American pharmaceutical industry transformed itself 
during the 1940s. University of California, Berkeley, 
Berkeley, November 2008.
5Global pharma looks to India: Prospects for growth; PWC 
Report.
6Pharmaceutical Sector Assessment in Ethiopia December 
2017 WHO and World Bank
medicines lists and medicines that 
are manufactured. 
4. To explore how collaborations, 
financing, research links, and 
technology transfer can be 
harnessed to not only boost local 
production of quality essential 
medicines in the EAC region, but 
also increase access to affordable 
medicines.
From the study, this policy brief 
was developed. It proposes a clear 
pathway and mechanisms for the 
enhancement of engagements across 
several industries, including research 
institutions in the EAC region.
APPROACHES AND RESULTS
A survey was conducted in the 
pharmaceutical manufacturing 
industry, universities and research 
institutions in the EAC region. 
Information was obtained through 
comprehensive literature review, 
use of questionnaires, and formal 
meetings with key stake holders 
including the pharmaceutical 
manufacturing industry, Ministry of 
Health and Ministry of Trade and 
Industry. 
Local Pharmaceutical Production in 
EAC Region
There are about 60 pharmaceutical 
manufacturers in EAC and Ethiopia. 
Majority produce non-sterile 
products – both beta and non-beta 
lactams; thus, demonstrating their 
level of competence in production 
of medicines. The major focus is 
on solids (capsules/tablets). The 
industry is limited in the capability 
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of manufacturing a whole range of 
essential medicines. This is mainly 
due to lack of technical, financial 
and human capacity to manufacture 
these products. Pharmaceutical 
partnership is a great collaborative 
strategy that manufacturers can use 
to exploit synergies in the application 
and utilisation of knowledge and 
resources, so as to help increase 
the range of products being 
manufactured. Technology transfer 
and joint ventures are initiatives that 
can be harnessed to improve access 
to essential medicines. Examples 
of successful technology transfer 
enterprises in the region are Universal 
Corporation Limited/Strides-Shasun 
Merger (Kenya) and CIPLA/Quality 
Chemical Industries Limited (Uganda). 
Like many African countries, Kenya 
lacks sufficient technical, financial and 
human capacity to produce adequate 
medicines to meet the country’s 
demand. This study established 
that the local pharmaceutical 
manufacturers in Kenya produced 
only 28% of the national essential 
medicines.
Notably, LPPs in Kenya focus on few 
therapeutic categories (Exhibit 1) 
at the expense of the bigger need, 
as per the disease burden profile of 
the EAC region and country. It is also 
noteworthy that LPPs are hesitant to 
engage in new molecule development 
that have high potential safety risks 
and/or narrow therapeutic indices. 
They also have a high product 
development cost. Most companies 
indicated that their product portfolio 
was based on market demand, and 
not necessarily on the need to develop 
new products to address government 
priorities, mainly because they are 
unsure of the government priorities 
and support. The industry’s main 
agenda was tailored towards profit 
and not the needs of the country in 
regard to essential medicines.
There is potential for growth in 
pharma research in the region. There 
are efforts to promote R&D work at 
Muhimbili School of Pharmacy, the 
Kilimanjaro School of Pharmacy in 
Tanzania supported by GIZ and the 
Kenya Medical Research Institute 
(KEMRI) but they are at the nascent 
stages. Furthermore, the region 
has many universities with schools 
offering courses in biological and 
other sciences, chemistry and more 
than 10 schools of pharmacy that 
can collaborate with the pharma 
industry and work towards achieving 
the national research and medicines 
agenda. 
However, the universities and research 
institutions in EAC have made no 
effort to create linkages with the 
Exhibit 1: Pharmaceutical products manufactured in Kenya
pharmaceutical industry. Most of 
the research that is perfomed is for 
academic publishing and has not 
resulted in innovation that is useful 
for the pharma industry. There 
is a glaring disconnect between 
academia, research institutes, the 
pharmaceutical industry and the 
government. The LPPs focus on a 
narrow set of products is an indication 
that there is no connection between 
the disease profile in the country 
and pharma manufacturing sector 
in terms of key priorities to address 
the national disease burden. The 
disease burden of the country should 
determine the priorities in selection 
of products to be developed and 
the subsequent product quality 
requirements.
Partnerships Proposed by the 
Pharmaceutical Sector
A symbiotic partnership is required 
(Exhibit 2). There is need to ensure 
that each player/stakeholder is 
benefiting from the partnership and 
this way it will be sustainable, in the 
following ways:
• The industry registers their needs 
with research institutions, for 
example product optimisation and 
new formulations among others.
• Research/academic institutions 
use their research facilities 
to carry out trial for the work 
requested by the industry. 
SCINNOVENT CENTRE - POLICY BRIEF NO. 10 4
• Once it is optimised and ready to 
be batch-tested, the researchers 
send the compounds (test 
products) to the pharma company 
to use their R&D facilities to 
initiate the tests at a production 
site.
• If the product does well and the 
process is optimised, it is then 
scaled up to commercial scale 
production.
• To ensure its success and 
sustainability, the government 
shall commit to buy xx% of the 
FPP ensuing from this process.
• On their part, the private sector 
will contribute back ~xx% of 
their sales per unit that will be 
committed to the R&D resource 
pool that supported the above 
work. The resource pool shall 
include already existing research 
funds from the National 
Research Fund targeted at health 
programmes
• The above cycle is repeated all 
through on a continuous basis.
Policy Implementation 
There are several policy documents in 
Kenya that are consistent with vision 
2030, an economic, social and political 
roadmap to move Kenya’s economic 
status to a middle-income country. 
They include the Universal Health 
Care, the Kenya Industrial policy and 
Kenya National Pharmaceutical policy. 
The driver for implementation in the 
pharmaceutical sector is the Kenya 
Pharmaceutical Sector Development 
Strategy (KPSDS). The KPSDS is a 
holistic approach encompassing 
seven strategic components namely, 
setting out a roadmap for industry to 
achieve GMP Standards, strengthening 
mechanisms for quality assurance of 
medicines in the distribution chain, 
strengthening regulatory capacity, 
accessing necessary financing for 
investment in the sector, devising 
time-limited incentives for industry, 
developing necessary human 
resources and developing common 
support services for the local pharma 
industry. 
There are lost opportunities when 
policy and implementations are not 
coherent. For example; in the 1990s, 
Kenya had several manufacturers 
producing anti-malarial products. 
Due to massive resistance to 
chloroquine and later Sulphadoxine 
Exhibit 2: Proposed Academia-Industry-Government Model
7Sarah Vugigi et al. Production Capacity of Pharmaceutical 
Manufacturing Industry in Kenya. East Cent. Afr. J. Pharm. 
Sci. 20, 2017, 3. 
8Global public action in health and pharmaceutical 
policies: politics and policy priorities IKD Working Paper 
No. 45 February 2009 Meri Koivusalo and Maureen 
Mackintosh
– Pyrimethamine in early 2010s, 
there was a deliberate change in 
therapy to the artemisinin-based 
combination therapy (ACT). However, 
the local production of anti-malarial 
products decreased substantially as a 
result of this change7. This is because 
Artemether/ Lumefantrine (AL) 
procurement by the government is 
donor-funded.
Most local manufacturers however 
are not eligible due to international 
prerequisites that participation is 
only open to manufacturers with 
WHO prequalification (PQ) status. 
Malaria at that time was the leading 
cause of morbidity. There were no 
initiatives for local sources for AL or 
other recommended therapies for 
malaria. Meri Koivusalo and Maureen 
Mackintosh cite malaria as one of the 
failure vertical programmes8 for lack 
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of integration with other strategies. It 
is important to recognise that changes 
in policy at international fora may be 
detrimental to an unprepared local 
industry.
The current disconnect between 
the national priorities and the local 
pharmaceutical industry arises 
from the fact that the government 
is not driving the industry towards 
manufacturing products according 
to the public sector needs. The 
weaknesses stated herein may be 
mitigated through the following 
actions, for enhancement of 
medicines access through 




• A high level government advisory 
panel on pharmaceuticals 
development should be 
established to collect, collate and 
disseminate data that is necessary 
to attract investment in the sector. 
It will also provide a forum to 
bring government, industry and 
academic/research institutions 
to identify national priority 
needs that are relevant to the 
pharmaceutical manufacturing 
industry. 
• Establish industry-research 
institution partnership for product 
innovation and research in line 
with the public health needs, 
especially essential medicines. 
This should include exploring 
traditional medicines as a source 
of medicines. This partnership 
shall run on the strength of 
product development, intellectual 
property agreements and 
assurance. 
Respective institutions and 
national governments should 
encourage, motivate and 
wherever possible, facilitate the 
agreements and guarantees, 
especially those ralated to LPPs 
and disease burden. 
• The region should harness 
the potential of their research 
institutions capabilities to develop 
new products through structured 
collaborations and partnerships 
that can be funded by the public 
to address the priorities in line 
with the national disease burden. 
This structured approach should 
ensure that the positive outcomes 
of these research/devlopment 
work benefits the citizenry. 
• Develop additional incentives and 
harmonise the incentive regime 
to catalyse growth and expansion 
of LPP scope to address the UN 
Sustainable Development Goal 
No.3 and disease burden. For 
example, the need to consider 
tax rebates for LPP that invest in 
quality improvements and R&D 
and also fund basic research in 
this industry. 
CONCLUSION 
The government should derive the 
R&D agenda for the pharmaceutical 
industry. There is need to establish 
a structured process to collect, 
synthesise and disperse data that is 
vital to guide industry and academic/
research institutions on national 
priority R&D needs. 
This necesitates a symbiotic linkage 
between universities/research 
institutions and the pharma industry 
on collaborative arrangements and 
sharing of knowledge in health and 
pharmaceutical research priorities 
for development targeted towards 
improved access to essential 
medicines.
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